Please note: The information displayed on this page might be outdated.
CerSci Therapeutics: Developing non-opioid pharmaceutical treatment options for the alleviation of acute and chronic pain. Lead candidate CT-044 currently in Ph 1 Safety and Tolerability Studies in human volunteers, data expected 2020. First-In-Class mechanism of action (Reactive Species Decomposition Accelerant -RSDAx). Initially developing for post-operative pain management and diabetic neuropathy with potential for future exploration in neurodegenerative diseases, opioid use disorder and migraines.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - West South Central
Clinical Stage
Phase l or ll, Pre-Clinical Stage
Disease Space
Central Nervous System, Pain
Industry
Biotechnology, Pharmaceuticals
Listing
Private
Website:
Profiles:
Address:
1601 Elm Street
Floor 33
Dallas, TX 75201
United States

Company Participants at Solebury Trout CEO & Investor Ski Conference 2020

  • Lucas Rodriguez, MS, PhD, CEO